Aquiti participated in Curlim’s 1.5 M€ seed financing.
Curlim is a biotech company focused on developing innovative therapies for hereditary peripheral neuropathies, particularly Charcot-Marie-Tooth disease type 1A (CMT1A), using advanced nanotechnology
Curlim is a biotech company focused on developing innovative therapies for hereditary peripheral neuropathies, particularly Charcot-Marie-Tooth disease type 1A (CMT1A), using advanced nanotechnology.